The long-term effect of community-based health management on the elderly with type 2 diabetes by the Markov modeling

Archives of Gerontology and Geriatrics

Volumn 59, Issue 2, 2014, Pages 353-359

  Chao, Jianqian ^a   Zong, Mengmeng ^a   Xu, Hui ^b   Yu, Qing ^b   Jiang, Lili ^a   Li, Yunyun ^a   Song, Long ^a   Liu, Pei ^a  

^a SOUTHEAST UNIVERSITY   (China)

^b Hospital of Qinghuai   (China)

Author keywords

Elderly diabetic patients; Health management; Long term effect; Markov model

Indexed keywords

HEMOGLOBIN A1C;

ADULT; AGED; ARTICLE; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE MONITORING; COHORT ANALYSIS; COMMUNITY BASED HEALTH MANAGEMENT; CONTROLLED STUDY; DEATH; DIABETES MELLITUS; DIABETIC PATIENT; DIET THERAPY; DISEASE COURSE; ELDERLY CARE; FEMALE; FINANCIAL MANAGEMENT; GLUCOSE BLOOD LEVEL; HEALTH CARE MANAGEMENT; HEALTH CARE PLANNING; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH PROMOTION; HIDDEN MARKOV MODEL; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; MICROANGIOPATHY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; PHYSICAL ACTIVITY; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; SELF CARE; SKILL; SOCIAL CARE; TELECONSULTATION; TRAINING; TREATMENT DURATION; CHINA; COMMUNITY CARE; DECISION MAKING; DIABETES MELLITUS, TYPE 2; HEALTH SERVICES RESEARCH; MIDDLE AGED; ORGANIZATION AND MANAGEMENT; PATIENT CARE PLANNING; QUESTIONNAIRE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CHINA; COMMUNITY HEALTH SERVICES; DECISION MAKING; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH SERVICES RESEARCH; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT CARE PLANNING; QUESTIONNAIRES;

EID: 84921688336     PISSN: 01674943     EISSN: 18726976     Source Type: Journal    
DOI: 10.1016/j.archger.2014.05.006     Document Type: Article

References (35)

1. Bombardier C., Maetzel A. Pharmacoeconomic evaluation of new treatment: Efficacy versus effectiveness studies?. The Annals of the Rheumatic Diseases 1999, 58(Suppl I):182-185.
2. Briggs A., Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics 1998, 13:397.
3. Cao Y. Decision analysis model in the economics of drug application. Chinese Pharmacy 2007, 18:562.
4. Carter K.J., Ritchey N.P., Castro F., Caccamo L.P., Kessler E., Erickson B.A. Analysis of three decision-making methods: A breast cancer patient as a model. Medical Decision Making 1999, 19:49-57.
5. Centers for Disease Control and Prevention (CDC), Diabetes Cost-Effectiveness Study Group The Cost-effectiveness of Screening for type 2 diabetes. JAMA: Journal of the American Medical Association 1998, 280:1757-1763.
6. Chen X.H., Cai J.M., Deng J.Z. Effect evaluation of the health management to the quality of life of diabetes in communities. China Medical Tribune 2009, 10:1368-1369.
7. China type 2 diabetes control guide 2011, Chinese Diabetes Association, Beijing University Medical Publishing Company, Beijing, (in China).
8. Clark C.M. The burden of hyperglycemia. Diabetes Care 1998, 21:c32-c34.
9. Ding Y.L. Statistical models to evaluate the affecting factors to survival number and the quality of type 2 diabetic patients 2001, (Doctoral thesis), Sichuan University, Chengdu, China.
10. Drabik A., Büscher G., Sawicki P.T., Thomas K., Graf C., Müller D., et al. Life prolonging of disease management programs in patients with type 2 diabetes is cost-effective. Diabetes Research and Clinical Practice 2012, 95:194-200.
11. Fonda S.J., Kedziora R.J., Vigersky R.A., Bursell S.E. Combining iGoogle and personal health records to create a prototype personal health application for diabetes self-management. Telemedicine Journal and E-Health 2010, 16:480-489.
12. Guo W.S., Marshall G. ORDMKV: A computer program fitting proportional odds model for multi-state Markov process. Computer Methods and Programs in Biomedicine 1995, 46:257-263.
13. Hay J., Jackson J., Luce B., Avorn J., Ashraf T. Panel 2: Methodological issues in conducting pharmacoeconomic evaluations - Modeling studies. Value in Health 1999, 2(2):78-81.
14. Hong Y., He D.H., Chang Z.H. Economic and mathematical models 2002, South China University of Technology Press, Guangzhou.
15. IDF diabetes atlas 2011, International Diabetes Federation, Brussels, Belgium. fifth ed.
16. Kay R. A Markov model for analyzing cancer markers and disease states in survival studies. Biometrics 1986, 42:855-865.
17. Longini I.M.J., Clark W.S., Byers R.H., Ward J.W., Darrow W.W., Lemp G.F., et al. Statistical analysis of the stages of HIV infection using a Markov model. Statistics in Medicine 1989, 8:831-843.
18. Lu L. Health Management Research of the elderly patients with type 2 diabetes in Community 2008, (MS thesis), China Medical University, Shenyang.
19. Marshall G., Garg S.K., Jackson W.E., Holmes D.L., Chase H.P. Factors influencing the onset and progression of diabetic retinopathy in subjects with insulin-dependent diabetes mellitus. Ophthalmology 1993, 100:1133-1139.
20. Nathan D.M., Kuenen J., Borg R., Zheng H., Schoenfeld D., Heine R.J., et al. Translating the A1C assay into estimated average glucose values?. Diabetes Care 2008, 31:1473-1478.
21. Oglesby Ak., Secnik K., Barron J., Al-Zakwani I., Lage M.J. The association between diabetes related medical costs and glycemic control: A retrospective analysis. Cost Effectiveness and Resource Allocation 2006, 4:1-28.
22. Palmer A.J., Roze S., Valentine W.J., Spinas G.A., Shaw J.E., Zimmet P.Z. Intensive lifestyle changes or metformin in patients with impaired glucose tolerance: Modeling the long-term health economic implications of the Diabetes Prevention Program in Australia, France, Germany, Switzerland, and the United Kingdom. Clinical Therapeutics 2004, 26:304-321.
23. Raîche M., Hébert R., Dubois M.F., Gueye N.R., Dubuc N. Yearly transitions of disability profiles in older people living at home. Archives of Gerontology and Geriatrics 2012, 55:399-405.
24. Sacco W.P., Bykowski C.A., Mayhew L.L., White K.E. Educational attainment moderates the effect of a brief diabetes self-care intervention. Diabetes Research and Clinical Practice 2012, 95:62-67.
25. Samoutis G.A., Soteriades E.S., Stoffers H.E., Philalithis A., Delicha E.M., Lionis C. A pilot quality improvement intervention in patients with diabetes and hypertension in primary care settings of Cyprus. Family Practice 2010, 27:263-270.
26. Schlundt D.G., Pichert J.W., Gregory B., Davis D. Eating and diabetes: a patient centered approach. Practical psychology for diabetes clinicians: effective techniques for key behavioral issues 2003, 73-82. American Diabetes Association. B. Anderson, R. Rubin (Eds.).
27. Sonnenberg F.A., Robert J.R. Markov Models in medical decision making: A practical guide. Medical Decision Making 1993, 13:322.
28. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998, 352:854-865. United Kingdom Prospective Diabetes Study Group.
29. Valentine W.J., Tucker D., Palmer A.J., Minshall M.F.V., Silberman C. Long-term cost-effectiveness of pioglitazone versus placebo in addition to existing diabetes treatment: A US analysis based on proactive. Value in Health 2009, 12:1-9.
30. Wang Q., Jin P.H. Applications of Markov model in health economic evaluation. China Health Statistics 2000, 17:86-88.
31. World Health Organization Definition, diagnosis and classifications of diabetes mellitus and its complications. Report of a WHO consultation, Part 1: Diagnosis and classification of diabetes mellitus 1999, WHO, Geneva.
32. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes - Estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1051.
33. Wong F.K.Y., Chow S.K.Y., Chan T.M.Y. Evaluation of a nurse-led disease management programme for chronic kidney disease: A randomized controlled trial. International Journal of Nursing Studies 2010, 47:268-278.
34. Ye Y.W., Wang Y.S., Shen Z.Y. The national clinical test operating rules 2006, Southeast University Press, China, Nanjing. 3rd ed.
35. Zhu C.R., Ni Z.Z., Sun K.H. Markov model for evaluation of long-term effects of rosiglitazone sodium in the treatment of type 2 diabetes. Health Research 2005, 34:355-358.